Cyclooxygenase-1 and cyclooxygenase-2 densities measured using positron emission tomography are not altered in the brains of individuals with stable multiple sclerosis
Restricted accessResearch articleFirst published online July, 2025
Cyclooxygenase-1 and cyclooxygenase-2 densities measured using positron emission tomography are not altered in the brains of individuals with stable multiple sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system that involves immune-mediated demyelination and axonal degeneration. Clinical imaging techniques play a critical role in diagnosing and assessing the prognosis of MS. Magnetic resonance imaging has been most frequently used to visualize demyelination and detect acute and chronic active lesions, which are key indicators of clinical course of illness. Previous research has also highlighted the effectiveness of translocator protein 18-kDa (TSPO) positron emission tomography (PET) imaging for identifying chronic active lesions and progressive pathology. Building on this work, the present study used PET imaging to explore the role of cyclooxygenase-1 and -2 (COX-1 and COX-2)—key enzymes involved in neuroinflammation—in individuals with MS. Five participants with MS were recruited, and lesions were identified using 7 Tesla MRI. No significant differences in COX radioligand binding were observed in the co-registered PET images between lesioned areas and normal-appearing brain tissues, nor between individuals with MS and healthy volunteers. The negative findings underscore the complexity of MS pathology and raise several important considerations for planning future studies using COX PET for imaging in MS.
ChoiSLakeSHarrisonDM.Evaluation of the blood-brain barrier, demyelination, and neurodegeneration in paramagnetic rim lesions in multiple sclerosis on 7 tesla MRI. J Magn Reson Imaging2024;
59: 941–951.
2.
BagnatoFSatiPHemondCC, et al.
Imaging chronic active lesions in multiple sclerosis: a consensus statement. Brain2024;
147: 2913–2933.
3.
CrossAHGelfandJMThebaultS, et al.
Emerging cerebrospinal fluid biomarkers of disease activity and progression in multiple sclerosis. JAMA Neurol2024;
81: 373–383.
4.
MarcilleMHurtado RuaSTyshkovC, et al.
Disease correlates of rim lesions on quantitative susceptibility mapping in multiple sclerosis. Sci Rep2022;
12: 4411.
5.
BagnatoFHametnerSYaoB, et al.
Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 tesla. Brain2011;
134: 3602–3615.
6.
BagnatoFHametnerSBoydE, et al.
Untangling the R2* contrast in multiple sclerosis: a combined MRI-histology study at 7.0 tesla. PLoS One2018;
13: e0193839.
7.
RissanenETuiskuJRokkaJ, et al.
In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand (11)C-PK11195. J Nucl Med2014;
55: 939–944.
8.
GiannettiPPolitisMSuP, et al.
Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study. Neurobiol Dis2014;
65: 203–210.
9.
GiannettiPPolitisMSuP, et al.
Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. Brain2015;
138: 110–119.
10.
PolitisMGiannettiPSuP, et al.
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology2012;
79: 523–530.
11.
SucksdorffMTuiskuJMatilainenM, et al.
Natalizumab treatment reduces microglial activation in the white matter of the MS brain. Neurol Neuroimmunol Neuroinflamm2019;
6: e574.
12.
OhUFujitaMIkonomidouVN, et al.
Translocator protein PET imaging for glial activation in multiple sclerosis. J Neuroimmune Pharmacol2011;
6: 354–361.
13.
HerranzEGianniCLouapreC, et al.
Neuroinflammatory component of gray matter pathology in multiple sclerosis. Ann Neurol2016;
80: 776–790.
14.
ColasantiAGuoQMuhlertN, et al.
In vivo assessment of brain white matter inflammation in multiple sclerosis with (18)F-PBR111 PET. J Nucl Med2014;
55: 1112–1118.
15.
VivashLO'BrienTJ.Imaging microglial activation with TSPO PET: lighting up neurologic diseases?J Nucl Med2016;
57: 165–168.
16.
KenouBVManlyLSRubovitsSB, et al.
Cyclooxygenases as potential PET imaging biomarkers to explore neuroinflammation in dementia. J Nucl Med2022;
63: 53S–59S.
17.
ChoiSHAidSBosettiF.The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci2009;
30: 174–181.
18.
RoseJWHillKEWattHE, et al.
Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion. J Neuroimmunol2004;
149: 40–49.
19.
CarlsonNGHillKETsunodaI, et al.
The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: implications for multiple sclerosis. J Neuroimmunol2006;
174: 21–31.
20.
ShresthaSKimMJEldridgeM, et al.
PET measurement of cyclooxygenase-2 using a novel radioligand: upregulation in primate neuroinflammation and first-in-human study. J Neuroinflammation2020;
17: 140.
21.
ShresthaSSinghPCortes-SalvaMY, et al.
3-Substituted 1,5-Diaryl-1 H-1,2,4-triazoles as prospective PET radioligands for imaging brain COX-1 in monkey. Part 2: selection and evaluation of [(11)C]PS13 for quantitative imaging. ACS Chem Neurosci2018;
9: 2620–2627.
22.
KimMJLeeJHJuarez AnayaF, et al.
First-in-human evaluation of [(11)C]PS13, a novel PET radioligand, to quantify cyclooxygenase-1 in the brain. Eur J Nucl Med Mol Imaging2020;
47: 3143–3151.
23.
ThompsonAJBanwellBLBarkhofF, et al.
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018;
17: 162–173.
24.
HarrisonDMAlletteYMZengY, et al.
Meningeal contrast enhancement in multiple sclerosis: assessment of field strength, acquisition delay, and clinical relevance. PLoS One2024;
19: e0300298.
25.
MizellRChenHLambeJ, et al.
Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI. Mult Scler2022;
28: 393–405.
26.
KurtzkeJF.Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983;
33: 1444–1452.
27.
ChoiSSpiniMHuaJ, et al.
Correction: blood-brain barrier breakdown in non-enhancing multiple sclerosis lesions detected by 7-Tesla MP2RAGE DeltaT1 mapping. PLoS One2022;
17: e0264452.
28.
MarquesJPKoberTKruegerG, et al.
MP2RAGE, a self bias-field corrected sequence for improved segmentation and T1-mapping at high field. Neuroimage2010;
49: 1271–1281.
29.
FujimotoKPolimeniJRvan der KouweAJ, et al.
Quantitative comparison of cortical surface reconstructions from MP2RAGE and multi-echo MPRAGE data at 3 and 7 T. Neuroimage2014;
90: 60–73.
30.
TustisonNJAvantsBBCookPA, et al.
N4ITK: improved N3 bias correction. IEEE Trans Med Imaging2010;
29: 1310–1320.
31.
PeiMNguyenTDThimmappaND, et al.
Algorithm for fast monoexponential fitting based on auto-regression on linear operations (ARLO) of data. Magn Reson Med2015;
73: 843–850.
BaoLLiXCaiC, et al.
Quantitative susceptibility mapping using structural feature based collaborative reconstruction (SFCR) in the human brain. IEEE Trans Med Imaging2016;
35: 2040–2050.
34.
SinghPShresthaSCortes-SalvaMY, et al.
3-Substituted 1,5-Diaryl-1 H-1,2,4-triazoles as prospective PET radioligands for imaging brain COX-1 in monkey. Part 1: synthesis and pharmacology. ACS Chem Neurosci2018;
9: 2610–2619.
35.
Cortes-SalvaMYShresthaSSinghP, et al.
2-(4-Methylsulfonylphenyl)pyrimidines as prospective radioligands for imaging cyclooxygenase-2 with PET-Synthesis, triage, and radiolabeling. Molecules2018;
23: 2850.
36.
YanXNoergaardMMorseCL, et al.
PET quantification in healthy humans of cyclooxygenase-2, a potential biomarker of neuroinflammation. J Nucl Med2025;
66: 398–404.
37.
HammersAAllomRKoeppMJ, et al.
Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp2003;
19: 224–247.
38.
GousiasISRueckertDHeckemannRA, et al.
Automatic segmentation of brain MRIs of 2-year-olds into 83 regions of interest. Neuroimage2008;
40: 672–684.
39.
DattaGColasantiAKalkN, et al. (
11)C-PBR28 and (18)F-PBR111 detect white matter inflammatory heterogeneity in multiple sclerosis. J Nucl Med2017;
58: 1477–1482.
40.
CashionJMYoungKMSutherlandBA.How does neurovascular unit dysfunction contribute to multiple sclerosis?Neurobiol Dis2023;
178: 106028.
41.
KennedyPGEGeorgeWYuX.The possible role of neural cell apoptosis in multiple sclerosis. Int J Mol Sci2022;
23: 7584.
42.
LoganJFowlerJSVolkowND, et al.
Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab1996;
16: 834–840.
43.
SucksdorffMRissanenETuiskuJ, et al.
Evaluation of the effect of fingolimod treatment on microglial activation using serial PET imaging in multiple sclerosis. J Nucl Med2017;
58: 1646–1651.
44.
GaoFGaoYMengF, et al.
The sphingosine 1-Phosphate analogue FTY720 alleviates seizure-induced overexpression of P-Glycoprotein in rat hippocampus. Basic Clin Pharmacol Toxicol2018;
123: 14–20.
45.
AnthonyDCDickensAMSenecaN, et al.
Anti-CD20 inhibits T cell-mediated pathology and microgliosis in the rat brain. Ann Clin Transl Neurol2014;
1: 659–669.
46.
DiskinCZottaACorcoranSE, et al.
4-Octyl-Itaconate and dimethyl fumarate inhibit COX2 expression and prostaglandin production in macrophages. J Immunol2021;
207: 2561–2569.
47.
DebruyneJCVan LaereKJVersijptJ, et al.
Semiquantification of the peripheral-type benzodiazepine ligand [11C]PK11195 in normal human brain and application in multiple sclerosis patients. Acta Neurol Belg2002;
102: 127–135.
48.
DebruyneJCVersijptJVan LaereKJ, et al.
PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol2003;
10: 257–264.
49.
DattaGViolanteIRScottG, et al.
Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis. Mult Scler2017;
23: 1469–1478.
50.
BanatiRBNewcombeJGunnRN, et al.
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain2000;
123(Pt 11): 2321–2337.
51.
RatchfordJNEndresCJHammoudDA, et al.
Decreased microglial activation in MS patients treated with glatiramer acetate. J Neurol2012;
259: 1199–1205.
SridharanSRaffelJNandoskarA, et al.
Confirmation of specific binding of the 18-kDa translocator protein (TSPO) radioligand [(18)F]GE-180: a blocking study using XBD173 in multiple sclerosis normal appearing white and grey matter. Mol Imaging Biol2019;
21: 935–944.
54.
Zanotti-FregonaraPPascualBRizzoG, et al.
Head-to-head comparison of (11)C-PBR28 and (18)F-GE180 for quantification of the translocator protein in the human brain. J Nucl Med2018;
59: 1260–1266.
55.
Zanotti-FregonaraPPascualBRostomilyRC, et al.
Anatomy of (18)F-GE180, a failed radioligand for the TSPO protein. Eur J Nucl Med Mol Imaging2020;
47: 2233–2236.
56.
NicholasRBrooksDOwenD.18F-GE180, a radioligand for the TSPO protein: not ready for clinical trials in multiple sclerosis. Eur J Nucl Med Mol Imaging2020;
47: 2242–2243.
57.
ChituVGokhanSNandiS, et al.
Emerging roles for CSF-1 receptor and its ligands in the nervous system. Trends Neurosci2016;
39: 378–393.
58.
HaganNKaneJLGroverD, et al.
CSF1R signaling is a regulator of pathogenesis in progressive MS. Cell Death Dis2020;
11: 904.
59.
HortiAGNaikRFossCA, et al.
PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proc Natl Acad Sci U S A2019;
116: 1686–1691.
60.
CoughlinJMDuYLesniakWG, et al.
First-in-human use of (11)C-CPPC with positron emission tomography for imaging the macrophage colony-stimulating factor 1 receptor. EJNMMI Res2022;
12: 64.
61.
van der WildtBKlockowJLMiaoZ, et al.
Discovery of a CSF-1R inhibitor and PET tracer for imaging of microglia and macrophages in the brain. Nucl Med Biol2022;
114–115: 99–107.
